Maria Santa Rocca1, Clara Benna2,3, Elena Goldin4, Andrea Di Nisio1, Luca De Toni1, Ilaria Cosci5, Alberto Marchet6, Donato Nitti2,3, Carlo Foresta7. 1. Department of Medicine, Unit of Andrology and Reproductive Medicine, University Hospital Padua, Via N. Giustiniani 2, 35128, Padua, Italy. 2. Department of Surgery Oncology and Gastroenterology, University of Padua, Padua, Italy. 3. First Surgical Clinic, University Hospital Padua, Padua, Italy. 4. Breast Unit, Azienda ULSS n.8 Berica, Vicenza, Italy. 5. Veneto Institute of Oncology IOV-IRCCS, Padua, Italy. 6. Multidisciplinary Day-Surgery Unit, University Hospital Padua, Padua, Italy. 7. Department of Medicine, Unit of Andrology and Reproductive Medicine, University Hospital Padua, Via N. Giustiniani 2, 35128, Padua, Italy. carlo.foresta@unipd.it.
Abstract
BACKGROUND: Breast cancer is the most common neoplasia among women in developed countries. The risk factors of breast cancer can be distinguished in modifiable and unmodifiable factors and, among the latter, genetic factors play a key role. Copy number variations (CNVs) are genetic variants that are classified as rare when present in less than 1% of the healthy population. Since rare CNVs are often cause of diseases, over the last years, their contribution in carcinogenesis has become a relevant matter of study. E2F1 is a transcriptional factor that plays an important role in regulating cell cycle and apoptosis. Its double and conflicting role is the reason why it acts both as oncogene and as tumour suppressor, depending on cell context. Since anomalies in expression or in number of copies of E2F1 have been related to several cancers, we aimed to study number of germline copies of E2F1 in women with breast cancer in order to better elucidate their contribution as predisposing factor to this tumour. METHODS: We performed, hence, a retrospective study on 222 Italian women with breast cancer recruited from October 2002 to December 2007. TaqMan CNV assay and Real-Time PCR were carried out to analyse, respectively, E2F1 CNV and E2F1 expression in the subjects of the study. Chi square test or Fisher's exact test and Student's t-test were used to calculate the frequency of CNVs and differences in continuous variables between groups, respectively. RESULTS: Intriguingly, we found that 10/222 (4.5%) women with breast cancer had more copies than controls (0/200, 0%), furthermore, the number of copies positively correlated with E2F1 gene expression in breast cancer tissue, suggesting that the constitutive gain of the gene could translate into an increased risk of genomic instability. Additionally, we found that altered E2F1 copies were present prevalently in the patients with contralateral breast cancer (20%) and all of them had a positive family history, both typically associated with hereditary cancer. CONCLUSIONS: Our findings suggest that copy number variations of E2F1 might be a susceptibility factor for breast cancer, however, further studies on large cohorts are to be performed in order to better delineate the phenotype linked to the gain of E2F1 copies.
BACKGROUND:Breast cancer is the most common neoplasia among women in developed countries. The risk factors of breast cancer can be distinguished in modifiable and unmodifiable factors and, among the latter, genetic factors play a key role. Copy number variations (CNVs) are genetic variants that are classified as rare when present in less than 1% of the healthy population. Since rare CNVs are often cause of diseases, over the last years, their contribution in carcinogenesis has become a relevant matter of study. E2F1 is a transcriptional factor that plays an important role in regulating cell cycle and apoptosis. Its double and conflicting role is the reason why it acts both as oncogene and as tumour suppressor, depending on cell context. Since anomalies in expression or in number of copies of E2F1 have been related to several cancers, we aimed to study number of germline copies of E2F1 in women with breast cancer in order to better elucidate their contribution as predisposing factor to this tumour. METHODS: We performed, hence, a retrospective study on 222 Italian women with breast cancer recruited from October 2002 to December 2007. TaqMan CNV assay and Real-Time PCR were carried out to analyse, respectively, E2F1 CNV and E2F1 expression in the subjects of the study. Chi square test or Fisher's exact test and Student's t-test were used to calculate the frequency of CNVs and differences in continuous variables between groups, respectively. RESULTS: Intriguingly, we found that 10/222 (4.5%) women with breast cancer had more copies than controls (0/200, 0%), furthermore, the number of copies positively correlated with E2F1 gene expression in breast cancer tissue, suggesting that the constitutive gain of the gene could translate into an increased risk of genomic instability. Additionally, we found that altered E2F1 copies were present prevalently in the patients with contralateral breast cancer (20%) and all of them had a positive family history, both typically associated with hereditary cancer. CONCLUSIONS: Our findings suggest that copy number variations of E2F1 might be a susceptibility factor for breast cancer, however, further studies on large cohorts are to be performed in order to better delineate the phenotype linked to the gain of E2F1 copies.
Entities:
Keywords:
Biomarker; Breast cancer; CNV; Copy number variations; E2F1
Authors: Xiaohong R Yang; Mark E Sherman; David L Rimm; Jolanta Lissowska; Louise A Brinton; Beata Peplonska; Stephen M Hewitt; William F Anderson; Neonila Szeszenia-Dabrowska; Alicja Bardin-Mikolajczak; Witold Zatonski; Richard Cartun; Daniza Mandich; Grzegorz Rymkiewicz; Marcin Ligaj; Stanislaw Lukaszek; Radzisaw Kordek; Montserrat García-Closas Journal: Cancer Epidemiol Biomarkers Prev Date: 2007-03 Impact factor: 4.254
Authors: Mark E Robson; Anne S Reiner; Jennifer D Brooks; Patrick J Concannon; Esther M John; Lene Mellemkjaer; Leslie Bernstein; Kathleen E Malone; Julia A Knight; Charles F Lynch; Meghan Woods; Xiaolin Liang; Robert W Haile; David J Duggan; Roy E Shore; Susan A Smith; Duncan C Thomas; Daniel O Stram; Jonine L Bernstein Journal: J Natl Cancer Inst Date: 2017-10-01 Impact factor: 13.506
Authors: F Casilli; I Tournier; O M Sinilnikova; F Coulet; F Soubrier; C Houdayer; A Hardouin; P Berthet; H Sobol; V Bourdon; D Muller; J P Fricker; C Capoulade-Metay; A Chompret; C Nogues; S Mazoyer; P Chappuis; P Maillet; C Philippe; A Lortholary; P Gesta; S Bézieau; C Toulas; L Gladieff; C M Maugard; D M Provencher; C Dugast; C Delvincourt; T D Nguyen; L Faivre; V Bonadona; T Frébourg; R Lidereau; D Stoppa-Lyonnet; M Tosi Journal: J Med Genet Date: 2006-09 Impact factor: 6.318
Authors: A Petrij-Bosch; T Peelen; M van Vliet; R van Eijk; R Olmer; M Drüsedau; F B Hogervorst; S Hageman; P J Arts; M J Ligtenberg; H Meijers-Heijboer; J G Klijn; H F Vasen; C J Cornelisse; L J van 't Veer; E Bakker; G J van Ommen; P Devilee Journal: Nat Genet Date: 1997-11 Impact factor: 38.330
Authors: C Cybulski; D Wokołorczyk; T Huzarski; T Byrski; J Gronwald; B Górski; T Debniak; B Masojć; A Jakubowska; B Gliniewicz; A Sikorski; M Stawicka; D Godlewski; Z Kwias; A Antczak; K Krajka; W Lauer; M Sosnowski; P Sikorska-Radek; K Bar; R Klijer; R Zdrojowy; B Małkiewicz; A Borkowski; T Borkowski; M Szwiec; S A Narod; J Lubiński Journal: J Med Genet Date: 2006-11 Impact factor: 6.318
Authors: Iris Kramer; Maartje J Hooning; Nasim Mavaddat; Michael Hauptmann; Renske Keeman; Ewout W Steyerberg; Daniele Giardiello; Antonis C Antoniou; Paul D P Pharoah; Sander Canisius; Zumuruda Abu-Ful; Irene L Andrulis; Hoda Anton-Culver; Kristan J Aronson; Annelie Augustinsson; Heiko Becher; Matthias W Beckmann; Sabine Behrens; Javier Benitez; Marina Bermisheva; Natalia V Bogdanova; Stig E Bojesen; Manjeet K Bolla; Bernardo Bonanni; Hiltrud Brauch; Michael Bremer; Sara Y Brucker; Barbara Burwinkel; Jose E Castelao; Tsun L Chan; Jenny Chang-Claude; Stephen J Chanock; Georgia Chenevix-Trench; Ji-Yeob Choi; Christine L Clarke; J Margriet Collée; Fergus J Couch; Angela Cox; Simon S Cross; Kamila Czene; Mary B Daly; Peter Devilee; Thilo Dörk; Isabel Dos-Santos-Silva; Alison M Dunning; Miriam Dwek; Diana M Eccles; D Gareth Evans; Peter A Fasching; Henrik Flyger; Manuela Gago-Dominguez; Montserrat García-Closas; José A García-Sáenz; Graham G Giles; David E Goldgar; Anna González-Neira; Christopher A Haiman; Niclas Håkansson; Ute Hamann; Mikael Hartman; Bernadette A M Heemskerk-Gerritsen; Antoinette Hollestelle; John L Hopper; Ming-Feng Hou; Anthony Howell; Hidemi Ito; Milena Jakimovska; Anna Jakubowska; Wolfgang Janni; Esther M John; Audrey Jung; Daehee Kang; C Marleen Kets; Elza Khusnutdinova; Yon-Dschun Ko; Vessela N Kristensen; Allison W Kurian; Ava Kwong; Diether Lambrechts; Loic Le Marchand; Jingmei Li; Annika Lindblom; Jan Lubiński; Arto Mannermaa; Mehdi Manoochehri; Sara Margolin; Keitaro Matsuo; Dimitrios Mavroudis; Alfons Meindl; Roger L Milne; Anna Marie Mulligan; Taru A Muranen; Susan L Neuhausen; Heli Nevanlinna; William G Newman; Andrew F Olshan; Janet E Olson; Håkan Olsson; Tjoung-Won Park-Simon; Julian Peto; Christos Petridis; Dijana Plaseska-Karanfilska; Nadege Presneau; Katri Pylkäs; Paolo Radice; Gad Rennert; Atocha Romero; Rebecca Roylance; Emmanouil Saloustros; Elinor J Sawyer; Rita K Schmutzler; Lukas Schwentner; Christopher Scott; Mee-Hoong See; Mitul Shah; Chen-Yang Shen; Xiao-Ou Shu; Sabine Siesling; Susan Slager; Christof Sohn; Melissa C Southey; John J Spinelli; Jennifer Stone; William J Tapper; Maria Tengström; Soo Hwang Teo; Mary Beth Terry; Rob A E M Tollenaar; Ian Tomlinson; Melissa A Troester; Celine M Vachon; Chantal van Ongeval; Elke M van Veen; Robert Winqvist; Alicja Wolk; Wei Zheng; Argyrios Ziogas; Douglas F Easton; Per Hall; Marjanka K Schmidt Journal: Am J Hum Genet Date: 2020-10-05 Impact factor: 11.025